Third Rock Ventures II L.P. 13D and 13G filings for Jounce Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:06 pm Sale |
2022-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
Third Rock Ventures II L.P. | 335,533 0.600% |
-3,794,934 (-91.88%) |
Filing |
| 2022-02-14 4:52 pm Sale |
2021-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
Third Rock Ventures II L.P. | 4,130,467 8.100% |
-8,209,361 (-66.53%) |
Filing |
| 2021-02-16 4:06 pm Sale |
2020-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
Third Rock Ventures II L.P. | 12,339,828 31.000% |
-939,292 (-7.07%) |
Filing |